HealthMap

Tacrine and Liver Toxicity in Dementia Patients

• Yes, absolutely. Tacrine (Cognex), which was one of the first acetylcholinesterase inhibitors approved for Alzheimer's disease and dementia, is well-documented for its significant potential to cause hepatotoxicity (liver toxicity).
• Elevated Liver Enzymes: Clinical data and patient monitoring show that a high percentage of patients taking tacrine experience significant elevations in serum transaminases (specifically ALT and AST).
• Mechanism and Reversibility: These liver function test abnormalities typically occur within the first several weeks of initiating therapy. Fortunately, the elevations are generally reversible upon prompt discontinuation of the drug.
• Monitoring Requirements: Due to this high risk of drug-induced liver injury, patients prescribed tacrine require frequent, mandatory monitoring of their liver enzyme levels (often biweekly for the first few months).
• Current Medical Status: Because of this severe adverse effect profile and the subsequent development of safer, better-tolerated alternatives (such as donepezil, rivastigmine, and galantamine), tacrine has largely been discontinued and withdrawn from the market in many countries.